Table 3. Univariate and multivariate survival analysis in patients with operable breast cancer.

	Disease-free survival				Overall survival
	univariate		multivariate		univariate		multivariate
	p	HR(95%CI)	p	HR(95%CI)	p	HR(95%CI)	p	HR(95%CI)
Age(vs.≤47)	0.405	0.7(0.3–1.6)	n.s.		0.524	0.7(0.3–1.9)	n.s.
Menopause(vs.no)	0.188	0.5(0.2–1.3)	n.s.		0.519	0.7(0.3–2.0)	n.s.
Tumor stage(Ⅰvs.Ⅱvs.Ⅲ)	<0.001	3.1(1.6–6.1)	0.939	n.s.	<0.001	4.3(1.9–9.9)	0.649	n.s.
Plasma fibrinogen, g/l	<0.001	4.7(2.0–11.2)	0.006	3.4(1.4–8.3)	<0.001	13.3(3.1–58.0)	0.002	10.1(2.3–44.6)
Histological grade (G1 vs. G2 vs.G3)	0.734	1.1(0.5–2.4)	n.s.		0.900	0.9(0.4–2.3)	n.s.
Tumor size(T1 &T2 vs. T3&T4)	<0.001	4.0(1.8–9.0)	0.061	n.s.	0.002	4.5(1.7–11.6)	0.118	n.s.
Lymph node involvement	<0.001	3.7(2.1–6.5)	<0.001	2.9(1.6–5.3)	<0.001	4.7(2.2–10.4)	0.006	3.2(1.4–7.3)
ER	0.379	1.5(0.6–3.8)	n.s.		0.209	2.2(0.6–7.6)	n.s.
PR	0.720	1.2(0.5–2.6)	n.s.		0.742	1.2(0.4–3.1)	n.s.
HER2	0.801	0.9(0.3–2.5)	n.s.		0.200	0.3(0–2.0)	n.s.
Ki-67	0.899	1.1(0.5–2.3)	n.s.		0.680	0.8(0.3–2.1)	n.s.
Molecular Type	0.761	1.1(0.7–1.5)	n.s.		0.706	0.9(0.6–1.5)	n.s.

n.s. = Not significant; CI = confidence interval; HR = hazard ratio.